Unfortunately the failed trial with NIH has spoiled aviptadil IMO. And without the FDA backing this is going nowhere. Hope they prove me wrong.
All the talk about NASDAQ was b.s. I'm sure they have been diluting the crap out of this to pay their high salaries and bonuses. Which means another r/s may be in the making in 2025 (or earlier).
The simple truth is, this company does not have a product that can generate reasonable revenues. It's always been one big pipe dream. FDA approval via COVID was the one big crap shoot with high profit potential. It's gone now.